Dr Phillips on Glofitamab Monotherapy in Relapsed/Refractory MCL

Tycel Phillips, MD, MPH, associate clinical professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the investigation of glofitamab monotherapy in relapsed/refractory mantle cell lymphoma (MCL).

A phase 1/2 trial (NCT03075696) explored single-agent glofitamab in patients with relapsed/refractory MCL who received at least 1 prior line of treatment. Previously reported data showed the agent elicited high responses during the trial, and findings on duration of response were presented at the 2022 ASH Annual Meeting.

Data showed that the overall response rate was higher among patients who received glofitamab at a dose of 2000 mg compared with 1000 mg, according to Phillips, who adds that trend also appeared in patients who received prior treatment with a BTK inhibitor. Patients who achieved a complete response (CR) experienced a median duration of CRof 10.0 months, and 20 of 27 complete responders remained in a CR at data cutoff, Phillips notes.

Regarding safety, 10 deaths occurred on study; 5 were related to progressive disease, 4 were due to COVID-19, and 1 was due to a cardiac event, Phillips says. None of the COVID-19 or cardiac deaths were considered related to treatment with glofitamab, Phillips concludes.